Deletion of Cd44 Inhibits Metastasis Formation of Liver Cancer in Nf2-Mutant Mice

Author:

Gerardo-Ramírez Monserrat1,Giam Vanessa1ORCID,Becker Diana1,Groth Marco2ORCID,Hartmann Nils3,Morrison Helen24,May-Simera Helen L.5ORCID,Radsak Markus P.6ORCID,Marquardt Jens U.7ORCID,Galle Peter R.1ORCID,Herrlich Peter2,Straub Beate K.3ORCID,Hartmann Monika1ORCID

Affiliation:

1. Department of Medicine I, University Medical Center of the Johannes Gutenberg University, 55131 Mainz, Germany

2. Leibniz Institute on Aging-Fritz Lipmann Institute (FLI), 07745 Jena, Germany

3. Institute of Pathology, University Medical Center of the Johannes Gutenberg University, 55131 Mainz, Germany

4. Faculty of Biological Sciences, Friedrich-Schiller University, 07745 Jena, Germany

5. Cilia Cell Biology, Institute of Molecular Physiology, Johannes Gutenberg University, 55128 Mainz, Germany

6. Department of Medicine III, University Medical Center of the Johannes Gutenberg University, 55131 Mainz, Germany

7. Department of Medicine I, University Medical Center Schleswig-Holstein, Campus Lübeck, 23558 Lübeck, Germany

Abstract

Primary liver cancer is the third leading cause of cancer-related death worldwide. An increasing body of evidence suggests that the Hippo tumor suppressor pathway plays a critical role in restricting cell proliferation and determining cell fate during physiological and pathological processes in the liver. Merlin (Moesin-Ezrin-Radixin-like protein) encoded by the NF2 (neurofibromatosis type 2) gene is an upstream regulator of the Hippo signaling pathway. Targeting of Merlin to the plasma membrane seems to be crucial for its major tumor-suppressive functions; this is facilitated by interactions with membrane-associated proteins, including CD44 (cluster of differentiation 44). Mutations within the CD44-binding domain of Merlin have been reported in many human cancers. This study evaluated the relative contribution of CD44- and Merlin-dependent processes to the development and progression of liver tumors. To this end, mice with a liver-specific deletion of the Nf2 gene were crossed with Cd44-knockout mice and subjected to extensive histological, biochemical and molecular analyses. In addition, cells were isolated from mutant livers and analyzed by in vitro assays. Deletion of Nf2 in the liver led to substantial liver enlargement and generation of hepatocellular carcinomas (HCCs), intrahepatic cholangiocarcinomas (iCCAs), as well as mixed hepatocellular cholangiocarcinomas. Whilst deletion of Cd44 had no influence on liver size or primary liver tumor development, it significantly inhibited metastasis formation in Nf2-mutant mice. CD44 upregulates expression of integrin β2 and promotes transendothelial migration of liver cancer cells, which may facilitate metastatic spreading. Overall, our results suggest that CD44 may be a promising target for intervening with metastatic spreading of liver cancer.

Funder

Deutsche Krebshilfe

Deutsche Forschungsgemeinschaft

Publisher

MDPI AG

Subject

General Medicine

Reference81 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA A Cancer J. Clin.,2021

2. Oncogenic driver genes and tumor microenvironment determine the type of liver cancer;Wang;Cell Death Dis.,2020

3. New concepts in the treatment of hepatocellular carcinoma;Sidali;United Eur. Gastroenterol. J.,2022

4. Gelband, H., Jha, P., Sankaranarayanan, R., and Horton, S. (2015). Cancer: Disease Control Priorities, The International Bank for Reconstruction and Development/The World Bank. [3rd ed.].

5. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals;Zhang;Dev. Cell,2010

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3